Key Highlights

  • INBX shares are trading up 9.29% to $96.84, against a prior close of $88.61.
  • The stock moved back above its 200-day moving average of about $91.47.
  • CEO Mark Lappe bought roughly $849,000 of stock at $84.56 on October 14.
  • Stifel has a price target of $325, and the consensus rating is Moderate Buy.
  • The next earnings report is expected on November 13.

Shares Reclaim the 200-Day Moving Average Without a Company Catalyst

Inhibrx Biosciences (NASDAQ:INBX) shares are trading up 9.29% to $96.84, rebounding after slipping below the 200-day moving average of about $91.47 on Monday, when the stock closed near $88.61. The stock is now back above that level and near its 50-day average of $103.80. No company-specific catalyst was identified in the reference material.

The move comes as healthcare is favored in a defensive rotation away from AI-linked stocks, though the State Street Health Care Select Sector SPDR ETF is little changed, down 0.09%. Biotech peers such as Kiniksa Pharmaceuticals (NASDAQ:KNSA) are also gaining on earnings.

Insider Buying and a $325 Target Frame Sentiment

Stifel reiterated a price target of $325, and the consensus rating is Moderate Buy. Insider buying has also drawn attention, including a purchase by CEO Mark Lappe of roughly $849,000 at $84.56 on October 14.

Shares opened at $88.52, and the 52-week range runs from $57.30 to $155.29. Inhibrx has a market cap of $1.43 billion and a loss of $8.88 per share, and its beta of 3.81 marks it as a highly volatile name.

Ozekibart and INBRX-106 Anchor an Oncology Pipeline

Inhibrx Biosciences, based in La Jolla, California, is a clinical-stage biotechnology company developing engineered biologic therapeutics for life-threatening conditions, with a primary focus on oncology. It uses proprietary modular protein engineering and single-domain antibody platforms. The pipeline is led by ozekibart (INBRX-109), a DR5 agonist, and INBRX-106, an OX40 agonist designed for solid tumors.

The company was formed as the oncology-focused successor to the legacy Inhibrx business after a large pharmaceutical company acquired the INBRX-101 program in 2024. It remains pre-commercial, and its value is driven by clinical progress, platform potential and future partnering or commercialization opportunities.

High Beta and a November 13 Earnings Date Set the Next Test

With no fresh fundamental news, the rebound looks driven by technical levels and sector flows. The next scheduled catalyst is the earnings report expected November 13, and investors will watch whether the stock holds above its 200-day average.